Efect of 25 weeks probiotic supplementation on immune function of HIV patients

Gut Microbes

Volumn 2, Issue 2, 2011, Pages

  Hummelen, Ruben ^a,e   Changalucha, John ^b   Butamanya, Nicodemus L ^c   Koyama, Tara E ^a   Habbema, J Dik F ^d   Reid, Gregor ^e  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b National Institute for Medical Research   (Netherlands)

^c Sekou Toure Regional Hospital   (Tanzania)

^d Kivulini Womens' Rights Organisation ^*  (Tanzania)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alanine transaminase; Alt; Anti retroviral treatment; Diarrhea; HIV; Immune function abbreviations: art; Lactobacillus; Probiotics; Sd; Standard deviation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; PLACEBO; PROBIOTIC AGENT; IMMUNOLOGIC FACTOR;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LACTOBACILLUS REUTERI; LACTOBACILLUS REUTERI RC 14; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS RHAMNOSUS GR 1; MAJOR CLINICAL STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOGENICITY; PHYSIOLOGY;

LACTOBACILLUS; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS;

ADMINISTRATION, ORAL; ADULT; CD4 LYMPHOCYTE COUNT; DIET THERAPY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; LACTOBACILLUS RHAMNOSUS; PLACEBOS; PROBIOTICS;

EID: 80053394176     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pabst R, Russell MW, Brandtzaeg P. Tissue distribution of lymphocytes and plasma cells and the role of the gut. Trends Immunol 2008; 29:206-8.
2. Kotler D P, Reka S, Borcich A, Cronin WJ. Detection, localization and quantitation of HIV-associated antigens in intestinal biopsies from patients with HIV. Am J Pathol 1991; 139:823-30.
3. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761-70.
4. Lim SG, Condez A, Poulter LW. Mucosal macrophage subsets of the gut in HIV: Decrease in antigen-presenting cell phenotype. Clin Exp Immunol 1993; 92:442-7.
5. Lim SG, Menzies IS, Lee CA, Johnson MA, Pounder RE. Intestinal permeability and function in patients infected with human immunodeficiency virus. A comparison with coeliac disease. Scand J Gastroenterol 1993; 28:573-80.
6. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008; 46:757-8.
7. Wolf BW, Wheeler KB, Ataya DG, Garleb KA. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol 1998; 36:1085-94.
8. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
9. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, et al. Microbial transloca-tion induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24:1281-90.
10. Redd AD, Eaton KP, Kong X, Laeyendecker O, Lutalo T, Wawer MJ, et al. C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of microbial translocation. J Acquir Immune Defic Syndr 2010; 54:556-9.
11. Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, et al. Microbial translocation, the innate cytokine response and HIV-1 disease progression in Africa. Proc Natl Acad Sci USA 2009; 106:6718-23.
12. Deeks SG. Immune dysfunction, inflammation and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17:118-23.
13. UNAIDS. MDG6: Six things you need to know about the AIDS response today. September 2010 Cited 2010-10-01, Availale from URL:www.data.unaids.org/pub/Report/2010/20100917_mdg6_report_en.pdf
14. FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Expert Consultation Report. October 2001, Cited 2010-10-01, Available from URL:www.who.int/food-safety/publications/fs_management/en/probiotics.pdf
15. Anukam KC, Osazuwa EO, Osadolor HB, Bruce AW, Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/ AIDS patients. J Clin Gastroenterol 2008; 42:239-43.
16. Trois L, Cardoso EM, Miura E. Use of probiotics in HIV-infected children: A randomized double-blind controlled study. J Trop Pediat 2008; 54:19-24.
17. Irvine SL, Hummelen R, Hekmat S, Looman CW, Habbema JD, Reid G. Probiotic yogurt consumption is associated with an increase of CD4 count among people living with HIV/AIDS. J Clin Gastroenterol 2010; 44:201-5.
18. Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: An investigation of age-related immunological changes. J Clin Immunol 2001; 21:264-71.
19. Reddy BS, Macfie J, Gatt M, Larsen CN, Jensen SS, Leser TD. Randomized clinical trial of effect of syn-biotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br J Surg 2007; 94:546-54.
20. Lutgendorff F, Akkermans LM, Söderholm JD. The role of microbiota and probiotics in stress-induced gastrointestinal damage. Cur Mol Med 2008; 8:282-98.
21. Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, et al. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol 2008; 14:2029-36.
22. Baroja ML, Kirjavainen P V, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007; 149:470-9.
23. Salminen MK, Tynkkynen S, Rautelin H, Poussa T, Saxelin M, Ristola M, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiret-roviral therapy: A randomized, placebo-controlled, crossover study. HIV Clin Trials 2004; 5:183-91.
24. Hummelen R, Changalucha J, Butamanya NL, Cook A, Habbema JD, Reid G. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int J Gyn Obstet 2010; 111:245-8.
25. Nugent R, Krohn MA, Hillier S. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram Stain interpretation. J Clin Microbiol 1991; 29:297-301.
26. WHO Diarrhoeal disease Factsheet No 330, Augustus 2009 Cited 10-01-2010, Available from URL: www. who.int/mediacentre/factsheets/fs330.
27. American Society for Clinical Laboratory Science, Biochemistry, Cited 09-15-2010, Available from URL: www.ascls.org/labtesting/labchem.asp
28. Reid G, Gaudier E, Guarner F, Huffnagle GB, Macklaim J, Murcia Munoz A, et al. Responders and non-responders to probiotic interventions: How can we improve the odds? Gut Microbes 2010; 1:200-4.
29. Lima AA, Silva TM, Gifoni AM, Barrett LJ, McAuliffe I T, Bao Y, et al. Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil. Am J Gastroenterol 1997; 92:1861-6.
30. Kassu A, Mohammad A, Fujimaki Y, Moges F, Elias D, Mekonnen F, et al. Serum IgE levels of tuberculosis patients in a tropical setup with high prevalence of HIV and intestinal parasitoses. Clin Exper Immunol 2004; 138:122-7.
31. Wright DN, Nelson RP, Ledford DK, Fernandez-Caldas E, Trudeau WL, Lockey RF. Serum IgE and human immunodeficiency virus (HIV) infection. J Allergy Clin Immunol 1990; 85:445-52.
32. Mazengera LR, Nathoo KJ, Rusakaniko S, Zegers BJ. Serum IgG subclasses levels in paediatric patients with pneumonia. Cent Afr J Med 2001; 47:142-5.
33. Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach JT, Hörmannsperger G, et al. Safety assessment of probiotics for human use. Gut Microbes 2010; 1:164-85.
34. Hummelen R, Vos P, van't Land B, van Norren K, Reid G. Altered host-microbe interaction in HIV: A target for intervention with pro and prebiotics. Int Rev Immunol 2010; 29:485-513.
35. Reid G. The potential role for probiotic yogurt for people living with HIV/AIDS. Gut Microbes 2010; 1:1-4.